Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Arcturus Therapeutics Holdings (ARCT) Gains from Equity Investments (2019 - 2020)

Arcturus Therapeutics Holdings' Gains from Equity Investments history spans 2 years, with the latest figure at $100000.0 for Q2 2020.

For Q2 2020, Gains from Equity Investments changed N/A year-over-year to $100000.0; the TTM value through Jun 2020 reached $551000.0, changed N/A, while the annual FY2020 figure was $263000.0, 952.0% up from the prior year.
Gains from Equity Investments reached $100000.0 in Q2 2020 per ARCT's latest filing, down from $163000.0 in the prior quarter.
In the past five years, Gains from Equity Investments ranged from a high of $288000.0 in Q1 2019 to a low of $100000.0 in Q2 2020.